Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

Phase 2

Terminated

Conditions: Colon Cancer
Adenocarcinoma

Interventions: Drug: XELOX
Drug: XELIRI
Drug: Bevacizumab

Registration Number: NCT00127036

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Brief Summary: The purpose of this study is to determine if the investigators can predict the sensitivity or resistance of colon cancer to the two available first line chemotherapy agents.

Detailed Description: Colorectal cancer is the third largest cause of cancer mortality in the United States. The treatment of metastatic colorectal cancer is undergoing rapid improvement. Currently, there are two major chemotherapy regimens, which can both be combined with anti-angiogenesis treatment. These regimens are 5-Fluorouracil (5-FU) + irinotecan and 5-FU + oxaliplatin. Each therapy has roughly similar rates of response, but it is unclear which specific therapy would benefit which patients. The advent of genome wide expression analysis provides a tool to analyze these differences. In the microarray analysis of colon cancer outcome trial, sponsored by the National Institutes of Health (NIH) and Moffitt Cancer Center, patients with newly diagnosed metastatic colon cancer are biopsied and samples are preserved in ribonucleic acid (RNA) later. Patients are then randomized to either one of two state of the art regimens: capecitabine + irinotecan + avastin (bevacizumab) or capecitabine + oxaliplatin + avastin. Response to chemotherapy, time to progression, and overall survival are end points of this trial. Once accrual of patients has been met, the investigators will compare genome wide expression patterns for each group.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 65

Inclusion Criteria

Provide written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Patients with metastatic, Response Evaluation Criteria In Solid Tumors (RECIST) measurable, adenocarcinoma of the colon and/or rectum are eligible provided their disease is metastatic to the liver. The liver metastatic disease should be confirmed cytologically or histologically at the time of study biopsy or prior to the study biopsy. All pre-study scans documenting disease must be done < 4 weeks prior to registration.
Patients must have had no prior treatment with either irinotecan or oxaliplatin.
Prior adjuvant therapy with fluoropyrimidine is allowed.
Prior radiotherapy is allowed, but patients should have measurable disease outside the radiation port and/or progressive disease within the previously radiated volume. In addition, it must be at least 2 weeks since administration of radiation therapy and all signs of toxicity must have abated.
Patients must have adequate renal and hepatic function (creatinine < 1.6 and calculated creatinine clearance [Cockcroft-Gault equation] > 60 ml/min; bilirubin < 2.0; and serum glutamic oxaloacetic transaminase [SGOT] less than 3 x normal limits) obtained within 4 weeks prior to registration.
Alkaline phosphatase < 2.5 x upper normal limit (or < 5 x upper normal limit in the case of liver metastases or < 10 x upper normal limit in the case of bone disease)
Patients must have absolute neutrophil count (ANC) > 1500/mm³ and platelet count > 100,000/mm³ within 4 weeks prior to registration.
Have a negative serum or urine pregnancy test within 7 days prior to starting therapy (female patients of childbearing potential)

Exclusion Criteria

Pregnant and breast-feeding women are excluded from the study because effects on the fetus are unknown and there may be a risk of increased fetal wastage.
Women of childbearing potential with either a positive or no pregnancy test (serum or urine) at baseline. Women/men of childbearing potential not using a reliable and appropriate contraceptive method. (Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential.) Patients will agree to continue contraception for 30 days from the date of the last study drug administration.
Serious, uncontrolled, concurrent infection(s). Patients must have no evidence of significant active infection (e.g., pneumonia, peritonitis, wound abscess, etc.) at time of study entry.
Life expectancy < 3 months
Any prior fluoropyrimidine therapy (unless given in an adjuvant setting and completed at least 6 months earlier)
Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase (DPD) deficiency
Treatment for other carcinomas within the last 5 years, except cured non-melanoma skin and treated in-situ cervical cancer
Participation in any investigational drug study
Clinically significant cardiac disease of New York Heart Association Class III or greater (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months.
Evidence of central nervous system (CNS) metastases (unless CNS metastases have been stable for > 3 months) or history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake.
Other serious uncontrolled medical conditions that the investigator feels might compromise study participation
Major surgery, open biopsy, or significant trauma injury within 28 days prior to Day 0
Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome
Known, existing uncontrolled coagulopathy
Impaired renal function (estimated creatinine clearance < 60ml/min as calculated with Cockcroft-Gault equation
Unwillingness to give written informed consent
Unwillingness to participate or inability to comply with the protocol for the duration of the study
Urine protein: creatinine ratio > 1.0 at screening
Blood pressure of > 150/100 mmHg
Unstable angina
Clinically significant peripheral vascular disease
Arterial thrombotic events, stroke or transient ischemic attack (TIA) within the last 6 months

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
XELOX + Bevacizumab	XELOX	Arm A: Anticipated 75 Patients - Drug: XELOX (which is Capecitabine + Oxaliplatin) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression
XELIRI + Bevacizumab	XELIRI	Arm B: Anticipated 75 Patients - Drug: XELIRI (which is Capecitabine + Irinotecan) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression
XELOX + Bevacizumab	Bevacizumab	Arm A: Anticipated 75 Patients - Drug: XELOX (which is Capecitabine + Oxaliplatin) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression
XELIRI + Bevacizumab	Bevacizumab	Arm B: Anticipated 75 Patients - Drug: XELIRI (which is Capecitabine + Irinotecan) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression

Primary Outcome Measures

Name	Time	Method
Number of Participants Per Treatment Arm, Per Tumor Tissue Response Classifier	30 Days After End of Treatment - Average of 6 Months	Investigators would develop tumor tissue classifiers to predict response to the XELOX arm or XELIRI arm; with gene expression profiles on 75 patients on each of 2 arms, construct 2 classifiers to distinguish responders (complete responses, partial responses, stable disease) from non-responders (progressive disease).

Secondary Outcome Measures

Name	Time	Method
Number of Participants Per Treatment Arm, With Overall Survival (OS)	30 Days After End of Treatment - Average of 6 Months	Investigators planned to evaluate the overall survival of colorectal cancer (CRC) patients treated with XELOX + bevacizumab (Arm A) or XELIRI + bevacizumab (Arm B).
Number of Participants With Serious Adverse Events (SAEs)	30 Days After End of Treatment - Average of 6 Months	Review of Serious Adverse Events (SAEs) To assess the toxicity associated with Arms A and B. Response rates and toxicity rates for each arm were to be estimated and exact (using Casella's method) 95% confidence intervals for those proportions computed. With the anticipated 75 patients in each arm, these estimated proportions would have standard errors not exceeding 7%.

Trial Locations

Locations (12): St. Joseph's Candler Health System
🇺🇸
Savannah, Georgia, United States
Bay Area Oncology
🇺🇸
Tampa, Florida, United States
Fawcett Memorial Hospital
🇺🇸
Port Charlotte, Florida, United States
Tallahassee Memorial Hospital
🇺🇸
Tallahassee, Florida, United States
Space Coast Medical Associates
🇺🇸
Titusville, Florida, United States
North Broward Medical Center
🇺🇸
Deerfield Beach, Florida, United States
Florida Cancer Specialists
🇺🇸
Ft. Myers, Florida, United States
Broward General Medical Center
🇺🇸
Fort Lauderdale, Florida, United States
Southeast Nebraska Cancer Center
🇺🇸
Lincoln, Nebraska, United States
Center for Cancer Care & Research - Watson Clinic
🇺🇸
Lakeland, Florida, United States
Martin Memorial
🇺🇸
Stuart, Florida, United States
H. Lee Moffitt Cancer Center & Research Institute
🇺🇸
Tampa, Florida, United States